PR Newswire - Financial

Emisphere Technologies, Inc. Add to My Watchlist

(OTCBB: EMIS)

Detailed Quote

News

Last Price	0.67 (11.20.09 5:20 PM EST)
Change (%)	- (-)
Volume	49,403
Open	0.67
Previous Close	0.67
Day High	0.68
Day Low	0.67
Bid	0.66 x 2500
Ask	0.69 x 2500

Average Volume	115,539
Shares Outstanding	42.07M
Market Cap	28.2M
Year High	1.49
Year Low	0.42
Earnings Per Share	-0.71
P/E Ratio	-
Dividend	N/A
Yield	N/A

Intraday

3 Month

6 Month

1 Year

Symbol	Last	Change (%)
YNSKF	0.01	+0.00 (+0.00)
BOMSF	0.35	+0.00 (+0.00)
PTHLF	1.12	+0.00 (+0.00)
APH	0.62	-0.01 (-1.59%)
MS	0.34	+0.00 (+0.00)
BLLN	0.05	+0.00 (+0.00)
CRXX	1.07	+0.19 (+21.59%)

Mon, Sep 22, 2008
	Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment - PR Newswire
Tue, Aug 19, 2008
	Nicholas J. Hart Joins Emisphere as Vice President, Strategy and Development - PR Newswire
Mon, Aug 11, 2008
	Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results - PR Newswire
Thu, Aug 07, 2008
	Emisphere Technologies, Inc. to Hold Conference Call to Announce 2008 Second Quarter Financial Results - PR Newswire
Tue, Aug 05, 2008
	Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment - PR Newswire
More Featured Content

Thu, Nov 19, 2009
	Ebitda Results for Emisphere Technologies Released by Ebitda News - StockTrendNews.com e...
Tue, Nov 17, 2009
	Free Cash Flow for Emisphere Technologies - now available via Free-Cash-News - StockTrendNews.com f...
	Year over Year Revenue Comparisons for Emisphere Technologies Now Available by T12-NEWS - StockTrendNews.com s...
	Stockdiagnostics Releases Most Recent OPS Ranking for Emisphere Technologies - StockTrendNews.com o...
	Emisphere Technologies' CFFO Data Now Available from CFFO-NEWS - StockTrendNews.com c...
More News

Fri, Nov 06, 2009
	RxNews Recap for Wednesday 11-04-09 Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page. Lannett Company, Inc. (NYSE:LCI), a manufacturer of generic pharmaceuticals, announced the company will release its fiscal 2010 first-quarter financial results on Monday, November 9, 2009. Catalyst Health Solutions, Inc. (NASDAQ:CHSI), a pharmacy benefit management company, announced its financial results for the third quarter ended September 30, 2009. SuperGen, Inc. (Nasdaq:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced Mohammad Azab, M.D., Chief Medical Officer, will present at the Merriman Curhan Ford 6th Annual Investor Summit on Tuesday November 10, 2009 in New York. Unigene Laboratories, Inc. (OTC:UGNE) will release financial results for the quarter ended September 30, 2009, after the market closes on Monday, November 9, 2009. Emisphere Technologies, Inc. (OTC:EMIS) announced management will host a conference call to discuss the Company’s financial and operational results for the third quarter ended September 30, 2009 on Monday, November 9, 2009 at 10:00 AM EST. BioClinica™, Inc. (NASDAQ:BIOC), a global provider of clinical trial services, announced its financial results for the quarter and nine months ended September 30, 2009. Universal Detection Technology (OTC:UNDT), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats, announced it is expanding its product catalogue to include a consumer-ready kit for the detection of black mold. Emdeon® (NYSE:EM), a leading provider of healthcare revenue and payment cycle management solutions, announced its eRx Network® will provide real-time electronic billing solutions to retail pharmacies for the nation's top 25 medical payers in light of the dramatic increase in H1N1 vaccinations being administered by pharmacies. Phase Forward (NASDAQ:PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced its senior vice president and chief financial officer, Chris Menard, and senior vice president of integration and product strategy, Martin Young, will present at the 18th Annual Credit Suisse Healthcare Conference at the Arizona Biltmore Hotel in Phoenix, Arizona. Medidata Solutions (NASDAQ:MDSO), a leading global provider of hosted clinical development solutions, announced a multi-year contract extension with Shire plc (NASDAQ:SHPGY) for use of Medidata Grants Manager™ and CRO Contractor™ benchmarking and analysis tools for investigator site and contract research organization (CRO) trial budget planning and forecasting. Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), reported financial results for the quarter ended September 30, 2009, and provided details on further developments. AcuMedSpa Holdings, Inc. (OTC:AMSZ) is pleased to announce that it has reached an agreement with Santa Barbara Medical Innovations (SBMI) to become a preferred provider of the popular Zerona protocol which is a proven, non-invasive cold laser solution for unwanted body fat as well as for body slimming and contouring. Zerona has been featured in dozens of magazines and on TV shows such as "Rachael Ray," "Extra" and "The Doctors." Advanced Life Sciences Holdings, Inc. (OTC:ADLS), announced it will host a conference call and webcast discussing the Company's 2009 third quarter results on Tuesday, November 10, 2009 at 10:00 a.m. (EST). InterMune, Inc. (Nasdaq:ITMN) announced it has submitted an electronic New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Javelin Pharmaceuticals, Inc. (NYSE:JAV) announced its CEO, Martin J. Driscoll, and Stephen J. Tulipano, CFO, will host a conference call to discuss the Company's quarterly results for the period ending September 30, 2009. Lannett Company, Inc. (NYSE:LCI), a manufacturer of generic pharmaceuticals, announced the company will release its fiscal 2010 first-quarter financial results on Monday, November 9, 2009. Unilife Medical Solutions Limited (OTC:UNIFF) (Unilife Australia) entered into a Merger Implementation Agreement with Unilife Corporation (Unilife USA) to facilitate the proposed redomiciliation of the Unilife group in the United States of America (Proposed Transaction). Aeolus Pharmaceuticals, Inc. (OTC:AOLS) reported researchers from National Jewish Health and McGill University have completed a series of preliminary studies demonstrating that AEOL 10150 protects lungs from chlorine gas exposure in mice. Pro-Pharmaceuticals, Inc. (OTC:PRWP) announced it has closed a $310,000 tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants. Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Global Research & Development Center, Inc., announced data from a Phase 2 clinical trial of Hematide™ showing that Hematide increased hemoglobin and reduced or eliminated the need for blood transfusion in most patients with erythropoietin-induced pure red cell aplasia (PRCA). Alkermes, Inc. (NASDAQ:ALKS) announced its corporate presentation will be webcast live by Credit Suisse on Wednesday, November 11, 2009, at 5:00 p.m MT (7:00 p.m. ET) from the Arizona Biltmore Hotel in Phoenix, Arizona. Flamel Technologies (Nasdaq:FLML) expects to release its financial results for the third quarter of 2009 the morning of November 16th, before the market opening. Neurogen Corporation (NASDAQ:NRGN), a drug development company, announced it will release its third quarter 2009 financial results on Friday, November 6, 2009 before the opening of the U.S. financial markets. Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, reported financial and operating results for the quarter ended September 30, 2009. Genta Incorporated (OTC:GETA) announced the Company will release its third quarter 2009 financial results on Monday, November 16, 2009. Gilead Sciences, Inc. (Nasdaq:GILD) announced its corporate presentation will be webcast from the 18th Annual Credit Suisse Healthcare Conference in Phoenix. SurModics, Inc. (Nasdaq:SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, reported financial results for the fourth quarter and fiscal year ended September 30, 2009. - BioMedReports.Com Sy...
Fri, Jun 05, 2009
	Emisphere (NASDAQ:EMIS): Improving Drug Delivery Emisphere (NASDAQ:EMIS) is an emerging bio-pharma company specializing in the development of a drug delivery technology platform for the oral administration of therapeutic compounds which are either poorly absorbed or must be given through alternative routes such as injections. On 6/1/09, EMIS announced that Novartis (NYSE:NVS) and Nordic Bioscience have completed recruitment for the planned second multi-center Phase 3 study exploring the safety and efficacy of an oral formulation of salmon c (...)[More...] - home: iStockAnalyst....
Thu, Jun 04, 2009
	Emisphere (NASDAQ:EMIS): Improving Drug Delivery (EMIS, rated BUY) Emisphere (NASDAQ:EMIS) is an emerging bio-pharma company specializing in the development of a drug delivery technology platform for the oral administration of therapeutic compounds which are either poorly absorbed or must be given through alternative routes such as injections. On 6/1/09, EMIS announced that Novartis (NYSE:NVS) and Nordic Bioscience have completed recruitment for the planned second multi-center Phase 3 study exploring the safety and efficacy of an oral formulation of salmon calcitonin using Emisphere’s proprietary Eligen Technology to treat patients with osteoarthritis of the knee. This study, which is intended to be used to support a FDA regulatory approval filing in the U.S., includes more than 900 patients between the ages of 51-80 with a medical history and symptoms of knee osteoarthritis. The study is being conducted in Europe and the U.S., as well as other countries, and is a two year study. Oral calcitonin is also being investigated using Eligen Technology in a Phase 3 study for osteoporosis. Both indications for the compound are in Phase 3 development with over 6,000 patients enrolled in three clinical studies. The osteoporosis trial is a three year trial initiated in February 2007 and the two year osteoarthritis trial beginning in May 2007 with the second two year trial for osteoarthritis initiated in June 2008. On 5/26/09, EMIS announced data from a clinical study designed to assess the effect of oral administration of two peptides (GLP-1 and PYY3-36) utilizing Emisphere’s Eligen Technology on appetite suppression. The randomized, double-blind, placebo-controlled trial was conducted in 16 normal weight males between the ages of 18-40. The study concluded that these orally administered peptides, when delivered with Emisphere’s SNAC carrier, were rapidly absorbed from the gastrointestinal tract, leading to concentrations several times higher than endogenous hormone levels achieved after a standard test meal. Specifically, results showed that oral GLP-1 (2 mg tablet) alone and the combination of oral GLP-1 (2 mg tablet) plus PYY3-36 (1 mg tablet) induced a significant reduction in calorie intake although there was no synergistic effect when the two peptides were used in combination. The data was encouraging and will warrant further investigation in clinical trials for appetite suppression and the results further validate the Company’s Eligen Technology and SNAC carrier’s ability to improve the oral absorption of peptides. In June 2008, EMIS announced an exclusive deal with Novo Nordisk (NYSE:NVO) to develop and commercialize oral formulations of the latter’s proprietary GLP-1 receptor agonists for the potential treatment of Type 2 diabetes. Previously conducted clinical trials have confirmed that the Company’s SNAC drug delivery technology allows for the safe and rapid oral absorption of GLP-1. On 5/21/09, EMIS received a $500,000 milestone payment from MannKind (NASDAQ:MNKD) in connection with that Company’s recent FDA filing and acceptance of a NDA for Afresa as an inhaled, ultra rapid-acting insulin. In early 2008, EMIS sold the rights to certain drug delivery patents to MNKD for an initial payment of $1.5M, and an additional payment of $500,000 remains to be paid to EMIS no later than 10/5/10. In early May, EMIS reported 1Q09 financial results, which included a net loss of $5.1M and an operating loss of $4.7M compared to a net loss of $3.9M and an operating loss of $6.5M in the year-ago periods. Total operating expenses during 1Q09 were $4.7M versus $6.6M in the year-ago period. At the end of 1Q09, EMIS reported a cash/restricted cash balance of $4.2M, with sufficient capital resources through August 2009 as the Company evaluates both non-dilutive and traditional financing options. Additionally, EMIS achieved a key milestone as part of its cost cutting initiatives with a goal of reducing the Company’s cash burn rate to a level of $7-8M per year. Another important milestone achieved in early May occurred when the Company was informed by an independent expert panel of scientists that its SNAC carrier was provisionally designated as Generally Recognized as Safe (GRAS) for its intended application in combination with nutrients added to food and dietary supplements. Following a comprehensive evaluation of research and toxicology data, Emisphere’s SNAC was found to be safe at a dosage up to 250 mg per day when used in combination with nutrients to improve their dietary availability. Achieving final GRAS status will allow EMIS to bypass the FDA as it seeks to commercialize its drug delivery technology to improve the oral absorption of vitamins and other nutritional supplements, such as <font> the Company’s first target – vitamin B12 </font> . EMIS expects to achieve final GRAS status following the publication of two peer reviewed papers describing the toxicology of SNAC, currently scheduled for July/August in the International Journal of Toxicology . A pharmacokinetic study conducted by EMIS demonstrated that mean vitamin B12 peak blood levels were more than 10X higher for the Eligen B12 5mg formulation compared to a 5mg commercial formulation. In addition, the Eligen formulation was absorbed much quicker as it reached a peak concentration in just 30 minutes versus 6.8 hours for the standard commercial formulation. The overall absorption of B12 was increased by about 240% for the Eligen formulation compared to the standard formulation. On 4/1/09, Par Pharma (NYSE:PRX) announced that its wholly-owned subsidiary focused on the development of proprietary drug products, Strativa Pharma, acquired the global rights to Nascobal (Cyanocobalamin) Nasal Spray from QOL Medical, LLC. Nascobal Nasal Spray is an FDA approved prescription vitamin B12 supplement indicated to treat vitamin B12 deficiency, and the product represents the first and only once-weekly, self-administered alternative to B12 injections. Strativa Pharma paid $54.5M for the worldwide rights to Nascobal, which equates to nearly 7X the $8M in sales for the product during 2008. Based on the PRX acquisition, EMIS would be undervalued at its current market cap around $35M based on the potential for an orally available, high-dose B12 product only. A prescription strength B12 formulation that could be taken by mouth would quickly become the market leader as patients would prefer this route to an injection or a squirt up the nose. Other near-term opportunities are possible for poorly absorbed and widely used mineral supplements such as iron. Of course, EMIS has more than just the near-term opportunity for improved oral delivery of vitamins and nutritional supplements with three ongoing Phase 3 trials for oral calcitonin funded and being conducted by Novartis for the treatment of conditions with major commercial potential in osteoporosis and osteoarthritis. In addition, there is minimal risk of failure or toxicity in the trials since the effects of calcitonin are well characterized and EMIS is simply improving upon the delivery of the drug. Outstanding issues weighing on the share price include the obvious need for some type of funding or financing by August, submitting additional information by 6/26/09 to maintain the Company’s NASDAQ listing, two outstanding notes, and litigation related to the proprietary technology for the oral administration of vitamin B12 against a former consultant/employee of EMIS. In February 2009, the defendants filed a countersuit against EMIS and the Company believes the counterclaims are without merit and plans to further litigate the matter. Two outstanding notes payable include a $12.1M Novartis Note which matures on 12/1/09 and currently bears interest at a rate of 7%. EMIS may convert the Novartis Note at any time prior to maturity into a number of shares of its common stock equal to the principal, accrued, and unpaid interest to be converted divided by the then market price of our common stock, provided certain conditions are met. At the end of 1Q09, a portion of the Novartis Note was convertible into 7.54M shares of EMIS common stock. Conditions affecting this note include that the number of shares issued to Novartis, when issued, does not exceed 19.9% of the total shares of the Company’s common stock outstanding, that at the time of such conversion no event of default under the Note has occurred and is continuing, and that there is either an effective shelf registration statement in effect covering the resale of the shares issued in connection with such conversion or the shares may be resold by Novartis pursuant to SEC Rule 144. EMIS also has $18.85M in outstanding MHR Convertible Notes. The Convertible Notes are due on 9/26/12 and bear interest at 11% and are secured by a first priority lien in favor of MHR Institutional Partners on substantially all of the Company’s assets. Interest is payable in the form of additional Convertible Notes issued monthly through March 31, 2007 and then semi-annually beginning June 30, 2008, rather than in cash and we have the right to call the Convertible Notes after September 26, 2010 if certain conditions are satisfied. Further the Convertible Notes provide MHR with the right to require redemption in the event of a change in control, as defined, prior to September 26, 2009. Such required redemption would be at 102% and 101% of the then outstanding principal and interest in the years through September 26, 2008 and 2009, respectively. The Convertible Notes are convertible, at the sole discretion of MHR or any assignee thereof through September 25, 2010, into shares of our common stock at a price per share of $3.78. At March 31, 2009, the Convertible Notes were convertible into 5.5M shares of EMIS common stock. Despite the issues outlined above which are weighing on the current stock price, EMIS has a promising drug delivery with little in the way of pipeline risk for its Phase 3 oral calcitonin clinical trials since they involve the improved oral delivery of an already used hormone. In addition, the PRX acquisition at 7X sales ($54.5M) for a B12 nasal spray product is similar to the current enterprise value for EMIS ($60M). EMIS should be viewed as a call option trade at its current stock price just north of $1/share, with the potential for multi-bagger gains if the risk factors outlined above are resolved successfully. Disclosure: No positions. - SocialPicks
Fri, Aug 15, 2008
	Carl Icahn's Icahn Capital Boosts Stake in MOT, Cuts TWC, Shows EMIS Stake - StreetInsider.com 13...
Mon, Mar 17, 2008
	The Greek's Week Ahead - Holy Week! The Greek's Week Ahead is the most comprehensive "week ahead" market-moving event planner in existence. The week ahead will offer a shortened trading period due to Western Christianity’s celebration of Good Friday. Speaking of good Fridays, we have had a few doozies over the past several periods. Two weeks ago, the Employment Situation Report sent markets for a spin, and then last week Bear Stearns needed rescue when it could not find counter-parties willing to deal with it. Thank Benjamin, JP Morgan Chase and the New York Federal Reserve played savior and kept Bear liquid, and solvent for that matter. Unlike Eliot Spitzer, the market was having a relatively decent week until the Bear Stearns emergency. For the week, the Dow closed higher 0.5%, the S&P 500 moved lower 0.4% and the Nasdaq was unchanged. Four-week moving average mutual funds flows continued to show improvement for equity funds, with net inflows averaging $835 million. Still, money funds drew in $18.5 billion in comparison, but this continued a decreasing trend in the level of cash inflow to the sector. Overseas, every major European market closed lower for the week, except Belgium and also Spain on the heels of its election. Finland dropped the most, down 4.0%. The broad DJ STOXX Index fell 1.2%. In Asia, all major markets fell, with the Indonesian market leading the losers as it collapsed 10.6%. India moved 1.2% lower, Japan 4.35% and Hong Kong 3.5%. Gold closed the week just under $1,000 per troy ounce, at $999.50. Light sweet crude closed up $5, to $110.21 per barrel. Natural gas finished higher, to $9.87 per mmbtu. The dollar closed weaker to 1.5665 euros. Before the Bear Stearns blowup... last Friday morning’s Consumer Price Index for February seemed just the right fuel for a strong finish to the week when it offered data showing no change in prices. However, as it turns out, the period recorded completely excluded the recent price rise of oil and distillates, like for instance gasoline! Everyone who drives or has seen a newspaper headline over the past month knows that gasoline has marked record territory recently. So, it appears next month’s CPI will not be so pleasant. As usual, the Fed’s action to keep Bear alive spurred much debate. It smells of a bailout, and that always draws the ire of free market capitalists. There’s a moral hazard to rescuing one company that fails due to its own excessive risk taking. There’s a concern this might encourage haphazard risk management at other firms, since there’s an understanding that the Fed is there for rescue if necessary. However, The Greek disagrees with the moral hazard argument, since we view the alternative unacceptable. If not for this and recent Fed action, we expect the American economy would be well on its way now to depression, not just recession, and that stock prices would be much lower. The Week Ahead This week offers important barometers of manufacturing sector condition and a timely meeting of the Federal Reserve. Monday A new governor takes over in New York and an important area manufacturing barometer will be measured on Monday. The day's Empire State Manufacturing Survey and Industrial Production reports, and the Philadelphia Fed Survey on Thursday, threaten to show manufacturing activity deteriorated. In their last reporting, New York and Philly area manufacturing dropped off sharply. Bloomberg's consensus is looking for a March Empire State General Business Conditions Index level of -6.3. Economists are looking for a February decrease in industrial production of 0.1%, and capacity utilization of 81.3%, which compares to 81.5% in January. Monday’s Treasury International Capital Report will measure foreign demand for long-term U.S. securities in January. December’s data showed a decrease in foreign investment demand from the month just prior. Tuesday’s State Street Investor Confidence Index will show how Americans feel about the same topic. We expect neither group is very optimistic. The Current Account for Q4 is due early Monday morning, while the Housing Market Index for March is set for 1:00 PM release. Monday's most noteworthy earnings reports include Bear Stearns (NYSE: BSC), Conseco (NYSE: CNO), 4Kids Entertainment (NYSE: KDE), AES Corp. (NYSE: AES), Acusphere (Nasdaq: ACUS), Bruker Biosciences (Nasdaq: BRKR), Cosi (Nasdaq: COSI), Excel Maritime Carriers (NYSE: EXM), GeoMet (Nasdaq: GMET), Goldleaf Financial (Nasdaq: GFSI), Houston Wire & Cable (Nasdaq: HWCC), Neurogen (Nasdaq: NRGN), Ocean Power Tech (Nasdaq: OPTT), Perry Ellis (Nasdaq: PERY), Repros Therapeutics (Nasdaq: RPRX), Shuffle Master (Nasdaq: SHFL), Syntroleum (Nasdaq: SYNM), The PMI Group (NYSE: PMI), US BioEnergy (Nasdaq: USBE), Vicor (Nasdaq: VICR) and WCI Communities (NYSE: WCI). Tuesday Le Rogue Trader, Jerome Kerviel might be set free by a Parisian Court on Tuesday. Speaking of criminals, some consider recent Federal Reserve action as highway robbery of dollar value. Heading into last Friday, the treasury market had been forecasting that the Federal Open Market Committee would decide on a 50 basis point rate cut (half of a percentage point) this week. However, in the mayhem of Friday morning, rate cut expectations rose to as high as 100 basis points. More than a handful of economists would rather the Fed not cut rates this time around, considering the further damage it could do to the dollar. There’s well-founded concern that in mitigating recession, the Fed might also spur future inflation that could do even more and longer-lasting economic damage. However, we agree that the Fed has to face the challenge at hand first, before looking beyond to a potential problem. The Fed is hopeful prices will naturally find suppression due to decreased domestic demand for goods and services. Globalization, however, threatens to keep the overall supply/demand equation tight, and thus prices high. We expect the FOMC will cut rates by 50 basis points on Tuesday. The ICSC-UBS Weekly Same-Store Sales results last week surprised on the short side of recent trend. Sales rose only 1.6% last week, year-to-year, while retail sales were reported down 0.6% in February. We estimated that overall sales trends contrasted with same-store sales growth because of mounting store closures and slowing new store openings. Last week's CPI data proved benign, but February's PPI data is due out on Tuesday morning. Bloomberg's survey shows expectations for headline price increase of 0.4% and a Core PPI rise of 0.2%. February Housing Starts are seen measuring 990K, compared to 1.012 million reported in January. The aforementioned State Street Investor Confidence Index is due at 10:00 a.m. Tuesday's earnings reports include Adobe Systems (Nasdaq: ADBE), Darden Restaurants (NYSE: DRI), EnergySolutions (NYSE: ES), Gamestop (NYSE: GME), GenTek (Nasdaq: GETI), Goldman Sachs (NYSE: GS), Healthways (Nasdaq: HWAY), Lehman Brothers (NYSE: LEH), Radyne Corp. (Nasdaq: RADN), Somanetics (Nasdaq: SMTS), Tsakos Energy Navigation (NYSE: TNP) and more. Wednesday Wednesday brings the regular pre-market Mortgage Bankers' Association reporting of weekly mortgage activity. The Fed's action from early last week was partly intended to bring mortgage rates down. We'll see... At 10:30, the EIA's Petroleum Status Report gets yet another opportunity to pound common sense into oil prices, but does supply/demand matter when the valuing currency is losing its worth by the minute. Wednesday earnings reports include China Mobile (NYSE: CHL), General Mills (NYSE: GIS), Morgan Stanley (NYSE: MS), Nike (NYSE: NKE), Avalon Pharmaceuticals (Nasdaq: AVRX), Borders Group (NYSE: BGP), Charming Shoppes (Nasdaq: CHRS), Cintas (Nasdaq: CTAS), CLARCOR (NYSE: CLC), Discover Financial (NYSE: DFS), Emisphere Technologies (Nasdaq: EMIS), Guess (NYSE: GES), Herman Miller (Nasdaq: MLHR), Lindsay Corp. (NYSE: LNN), North American Palladium (AMEX: PAL), Petroleum Development (Nasdaq: PETD), Pinnacle Gas (Nasdaq: PINN), Ross Stores (Nasdaq: ROST), The Marcus Corp. (NYSE: MCS), Ulta Salon, Cosmetics and Fragrance (Nasdaq: ULTA) and more. Thursday Welcome to the witching hour, quadruple witching that is. Weekly Initial Jobless Claims are expected to measure 360K, after sticking at 353K last week. Leading Economic Indicators for February is set for Thursday reporting, and will give some further indication of how likely economic contraction is for the first quarter. Bloomberg's consensus is looking for a 0.3% decrease for February. The Philly Fed Survey, which scared the cheesesteak out of the market last month, is widely expected to sit in negative territory again this time around at -20.0. The EIA Natural Gas Report at 10:30 should again offer bearish data. Thursday's earnings include Carnival Corp. (NYSE: CCL), FedEx (NYSE: FDX), New York & Co. (NYSE: NWY), CRA Int'l (Nasdaq: CRAI), CryoCor (Nasdaq: CRYO), dELiA's(Nasdaq: DLIA), Genpact (NYSE: G), Global Options (Nasdaq: GLOI), Hellenic Telecommunications (NYSE: OTE), Luby's (NYSE: LUB), Palm (Nasdaq: PALM), Progress Software (Nasdaq: PRGS), Shoe Carnival (Nasdaq: SCVL), The Children's Place (Nasdaq: PLCE), Winnebago (NYSE: WGO), WorldSpace (Nasdaq: WRSP), Worthington Industries (NYSE: WOR) and more. Because of the holiday on Friday, U.S. equity and bond markets will be closed. Markets in Hong Kong, Singapore and the U.K. will also be closed. You can support "The Greek" by supporting our advertisers. Thank you. (disclosure) - Wall Street Greek
More Blogs

Fri, Aug 25, 2006
	Wall Street to Main Street: News, Views and Commentary: August 25, 2006 Time Warner, Sony, Apple Computer, Dell Inc, SanDisk, XM Satellite Radio, Sirius Satellite Radio - NAMC Radio
More Podcasts

11/09/09		Q3 2009 Earnings Archive for EMIS
09/09/09		Special Conference Emisphere Technologies to Present at the Rodman and Renshaw 11th Annual Healthcare Conference Archive for EMIS
08/11/09		Q2 2009 Earnings Archive for EMIS
05/07/09		Q1 2009 Earnings Archive for EMIS
03/10/09		Q4 2008 Earnings Archive for EMIS

Powered By: FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes.
All other data is delayed at least 20 minutes.
By accessing this page, you agree to the following terms and conditions.
Stock News provided by MarketMinute.com
Stock Analysis provided by SocialPicks Conference calls info supplied by OpenCompany
Fundamental data supplied by Mergent, Inc.
Stock quote data supplied by Telekurs